BBP240920C58000
- 0.00
- 0.000.00%
Virtus Lifesci Biotech Products Etf Newsroom
Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $116 Price Target
Ultragenyx Pharmaceutical Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $70 Price Target
Gilead Sciences Analyst Ratings
Aurinia Pharmaceuticals Analyst Ratings
JP Morgan Maintains Overweight on Travere Therapeutics, Raises Price Target to $23
Travere Therapeutics Analyst Ratings
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Kiniksa Draws Buy at Jefferies on Potential Blockbuster Status for Lead Drug
Kiniksa Pharmaceuticals Analyst Ratings
Marengo Therapeutics Enters Clinical Study Collaboration And Supply Agreement With Gilead Sciences
US stocks closed: Technology breaks through to lift the index, Nasdaq and S&P jointly achieve four consecutive gains.
① After four consecutive days of gains, the S&P 500 index is still 1.3% away from its historical high. ② Warren Buffett's deputy sold more than half of Berkshire Hathaway's positions, causing the stock price to fall for the seventh consecutive day. ③ AirPods Pro transforms into an OTC hearing aid, with FDA approval for Apple's hearing assistance software. ④ Gilead's HIV prevention drug delivers positive results once again.
Gilead Sciences Goes Ex-dividend Tomorrow
Gilead's "HIV prevention" drug has achieved amazing results again! The effectiveness rate is as high as 96%.
① The results showed that among the 2,180 participants in the lenacapavir group, there were only 2 new cases, and 99.9% of the participants did not become infected with HIV, resulting in a relative risk reduction of 96%. ② The press release also mentioned the results of the "PURPOSE 1" trial released in June - there were zero cases of HIV infection among the 2,134 women in the lenacapavir group.
What the Options Market Tells Us About Gilead Sciences
Gilead Posts Second Late-stage Win for Twice-yearly HIV Therapy
Gilead Shares Are Trading Higher After the Company Announced Interim Results From a Phase 3 Trial Showing That Twice-yearly Lenacapavir Reduced HIV Infections by 96%.
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
Piper Sandler Maintains Overweight on Gilead Sciences, Maintains $95 Price Target
TG Therapeutics Shares Are Trading Higher After It Was Announced the Stock Will Join the S&P SmallCap 600.